IFIT2 and metastatic melanoma: Indeed, a past study confirmed that IFIT2 is significantly up-expressed in patients who are not sensitive to anti-CTLA-4 therapy in metastatic melanoma [41], suggesting that the IFIT family may be useful for predicting the efficacy of immune checkpoint therapy.